{
  "source": "PA-Notification-Skyrizi.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1293-8\nProgram Prior Authorization/Notification\nMedication *Skyrizi® (risankizumab-rzaa) injection\n*This program applies to the subcutaneous formulations of Skyrizi\nP&T Approval Date 9/2019, 9/2020, 9/2021, 3/2022, 8/2022, 7/2023, 5/2024, 7/2024\nEffective Date 10/1/2024\n1. Background:\nSkyrizi is an interleukin-23 antagonist indicated for the treatment of moderate to severe plaque\npsoriasis in adults who are candidates for systemic therapy or phototherapy, active psoriatic\narthritis in adults, moderately to severely active Crohn's disease in adults, and moderately to\nseverely active ulcerative colitis in adults.\n2. Coverage Criteriaa:\nA. Plaque Psoriasis\n1. Initial Authorization\na. Skyrizi will be approved based on both of the following criteria:\n(1) Diagnosis of moderate to severe plaque psoriasis\n-AND-\n(2) Patient is not receiving Skyrizi in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), adalimumab, Stelara (ustekinumab), Tremfya\n(guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodalumab),\nIlumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Skyrizi will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Skyrizi therapy\n-AND-\n(2) Patient is not receiving Skyrizi in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), adalimumab, Stelara (ustekinumab), Tremfya\n(guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodalumab),\n© 2024 UnitedHealthcare Services, Inc.\n1\nIlumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\nAuthorization will be issu",
    "liq (brodalumab),\n© 2024 UnitedHealthcare Services, Inc.\n1\nIlumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\nB. Psoriatic Arthritis (PsA)\n1. Initial Authorization\na. Skyrizi will be approved based on both of the following criteria:\n(1) Diagnosis of active psoriatic arthritis\n-AND-\n(2) Patient is not receiving Skyrizi in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), adalimumab, Stelara (ustekinumab),\nTremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla\n(apremilast)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Skyrizi will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Skyrizi therapy\n-AND-\n(2) Patient is not receiving Skyrizi in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), adalimumab, Stelara (ustekinumab),\nTremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla\n(apremilast)]\nAuthorization will be issued for 12 months.\nC. Crohn’s Disease (CD)\n1. Initial Authorization for Maintenance Dosing\na. Skyrizi will be approved based on both of the following criteria:\n(1) Diagnosis of moderately to severely active Crohn’s disease\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n2\n(2) Patient is not receiving Skyrizi in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib),\nOlumiant (baricitinib), Rinvoq (upadacitinib), Stelara (ustekinumab)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Skyri",
    "), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib),\nOlumiant (baricitinib), Rinvoq (upadacitinib), Stelara (ustekinumab)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Skyrizi will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Skyrizi therapy\n-AND-\n(2) Patient is not receiving Skyrizi in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib),\nOlumiant (baricitinib), Rinvoq (upadacitinib), Stelara (ustekinumab)]\nAuthorization will be issued for 12 months.\nD. Ulcerative Colitis (UC)\n1. Initial Authorization\na. Skyrizi will be approved based on both of the following criteria:\n(1) Diagnosis of moderately to severely active ulcerative colitis\n-AND-\n(2) Patient is not receiving Skyrizi in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib), Stelara (ustekinumab), adalimumab]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Skyrizi will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Skyrizi therapy\n-AND-\n(2) Patient is not receiving Skyrizi in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n© 2024 UnitedHealthcare Services, Inc.\n3\n(golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib), Stelara (ustekinumab), adalimumab]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, U",
    "ber specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits, Medical Necessity, and/or Step Therapy may be in place.\n4. References:\n1. Skyrizi [package insert]. North Chicago, IL: AbbVie Inc.; June 2024.\nProgram Prior Authorization/Notification – Skyrizi® (risankizumab-rzaa)\nChange Control\n9/2019 New program\n9/2020 Annual review. Changed reauthorization duration to 12 months.\nUpdated reference.\n9/2021 Annual review with no changes to coverage criteria. Updated\nreference.\n3/2022 Clinical coverage criteria updated to add active psoriatic arthritis.\nUpdated reference.\n8/2022 Clinical coverage criteria and background updated to add Crohn’s\ndisease. Added state mandate footnote. Added Rinvoq as Janus kinase\ninhibitor example. Updated reference.\n7/2023 Updated not receiving in combination language to targeted\nimmunomodulator and updated examples.\n5/2024 Annual review with no changes to coverage criteria. Updated reference.\n7/2024 Updated clinical coverage criteria and background to add ulcerative\ncolitis. Updated reference.\n© 2024 UnitedHealthcare Services, Inc.\n4"
  ]
}